Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew H Wei

Showing results (1-10 of 181) with videos related to

Pageof 19
Sort By:
Blood|August 5, 2021
Fitness for intensive chemotherapy: a continuing conundrumAndrew H Wei
Blood|March 30, 2019
Maintenance therapy for AML: are we there yet?Andrew H Wei
Leukemia & Lymphoma|August 4, 2021
Post-transplant maintenance therapy for MDS and AML: a bridge too far or the beginning of a new era?Sun Loo, Andrew H Wei
Future Oncology (London, England)|March 26, 2021
The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromesDavid Kipp, Andrew H Wei
Haematologica|August 5, 2021
<i>FLT3-ITD</i> signals bad news for core binding factor acute myeloid leukemia unless trisomy 22 comes to the rescueSun Loo, Andrew H Wei
Blood|April 1, 2021
Taking aim at IDH in fitter patients with AMLAndrew H Wei, Naval Daver
Hematology. American Society of Hematology. Education Program|December 5, 2025
Triplet regimens for all: genomically agnostic approaches to improve on HMA + VEN in AML?William Nicol, Andrew H Wei
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2019
Incorporating Precision BH3 Warheads Into the Offensive Against Acute Myeloid LeukemiaMichael R Savona, Andrew H Wei
Blood|October 21, 2017
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AMLAndrew H Wei, Ing S Tiong
Leukemia & Lymphoma|April 10, 2008
Bortezomib: putting mantle cell lymphoma on death rowAndrew H Wei, Andrew W Roberts
Pageof 19

Showing results (1-10 of 181) with videos related to

Sort By:
Pageof 19
Blood|August 5, 2021
Fitness for intensive chemotherapy: a continuing conundrumAndrew H Wei
Blood|March 30, 2019
Maintenance therapy for AML: are we there yet?Andrew H Wei
Leukemia & Lymphoma|August 4, 2021
Post-transplant maintenance therapy for MDS and AML: a bridge too far or the beginning of a new era?Sun Loo, Andrew H Wei
Future Oncology (London, England)|March 26, 2021
The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromesDavid Kipp, Andrew H Wei
Haematologica|August 5, 2021
<i>FLT3-ITD</i> signals bad news for core binding factor acute myeloid leukemia unless trisomy 22 comes to the rescueSun Loo, Andrew H Wei
Blood|April 1, 2021
Taking aim at IDH in fitter patients with AMLAndrew H Wei, Naval Daver
Hematology. American Society of Hematology. Education Program|December 5, 2025
Triplet regimens for all: genomically agnostic approaches to improve on HMA + VEN in AML?William Nicol, Andrew H Wei
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2019
Incorporating Precision BH3 Warheads Into the Offensive Against Acute Myeloid LeukemiaMichael R Savona, Andrew H Wei
Blood|October 21, 2017
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AMLAndrew H Wei, Ing S Tiong
Leukemia & Lymphoma|April 10, 2008
Bortezomib: putting mantle cell lymphoma on death rowAndrew H Wei, Andrew W Roberts
Pageof 19